Computed from SEC EDGAR filings and closing prices — not copied from any wealth ranking. Dataset . How we calculate this.
Market capitalisation
$15.88B
101,649,181 shares Covers every share class this company has on file.
Insiders on file
18
people who have filed Form 3, 4 or 5 naming this issuer
Value of insider-held stock
$188.68M
from the holdings reported on Forms 3/4/5; this figure has no separate as-of date on file
Insider-held share of market cap
1.19%
insider-held value divided by market capitalisation
What NEUROCRINE BIOSCIENCES INC reports
Revenue and net income below are for fiscal period FY2025, the period label carried by this company’s own annual XBRL filings to the SEC. Fiscal years do not line up between companies — one company’s FY2026 can cover much the same months as another’s FY2025 — so compare the periods, not just the numbers.
Revenue
$2.86B
FY2025annual revenue, from this company’s own annual XBRL filings to the SEC
Net income
$478.60M
FY2025profit for the period, from this company’s own annual XBRL filings to the SEC
Employees
2,500
Yahoo Finance
Where the employee count comes fromi
Headcount comes from Yahoo Finance, not from a filing. The date beside it is the day we retrieved the figure — it is not the date the company counted its staff, and Yahoo does not publish that date. Unlike the SEC filings behind the other figures on this page, this one carries no open licence, so we publish the number and nothing else from that source.
Insiders at NEUROCRINE BIOSCIENCES INC
Shares is what each person last reported holding here.i
Everyone below has filed at least one insider report against this company.
Value is that share count priced at the same closing price used everywhere else on this site. A row priced from only some of a person’s securities says so — we do not quietly present a partial sum as a complete one.
Rows are grouped by the role each person reports.i
The role comes from the relationship boxes a person ticks on their own insider filings — officer, director, ten per cent owner — not from anything we infer. Somebody who is both an officer and a director appears once, in the combined group, so the row count still matches the figure at the top of this page. Where no filing states a role we say so instead of guessing one.
People who file insider reports against NEUROCRINE BIOSCIENCES INC.
MOption exercise or conversion May 21, 2026 position reported
Events from filings
Detected automatically in the filings linked below. Each headline is built from the numbers in those filings, not written by a model. Newest first; events older than 45 days stay listed and are marked as older.
Ingrid Delaet sold 8,433 NEUROCRINE BIOSCIENCES INC (NBIX) shares for $1,507,146 on Jul 9, 2026
Large trade for this person
Flagged because this trade was large compared with this person’s own earlier open-market trades in the same currency — not because it is large in absolute terms. A trade that is routine for one insider can be flagged for another.
Ingrid Delaet sold 8,433 NEUROCRINE BIOSCIENCES INC (NBIX) shares for $1,507,146 on Jul 9, 2026
Source: SEC EDGAR (United States); every row links to where it was published. Event computed Sep 14, 2026.
Julie Cooke sold 23,735 NEUROCRINE BIOSCIENCES INC (NBIX) shares for $3,701,454 on Jun 2, 2026
Large trade for this person
Flagged because this trade was large compared with this person’s own earlier open-market trades in the same currency — not because it is large in absolute terms. A trade that is routine for one insider can be flagged for another.
Julie Cooke sold 23,735 NEUROCRINE BIOSCIENCES INC (NBIX) shares for $3,701,454 on Jun 2, 2026
Total of the rows above: $3,701,454, in the currency the filings report.
Source: SEC EDGAR (United States); every row links to where it was published. Event computed Sep 14, 2026.
Julie Cooke sold 36,937 NEUROCRINE BIOSCIENCES INC (NBIX) shares for $5,770,377 on Jun 2, 2026
Unusual change in a direct holding
Flagged because the change that day in the shares this person holds directly was unusually large compared with their own earlier changes. The rows below are the open-market trades reported that day; under each share count is the balance the filing reports after that line.
Julie Cooke sold 36,937 NEUROCRINE BIOSCIENCES INC (NBIX) shares for $5,770,377 on Jun 2, 2026
Total of the rows above: $5,770,377, in the currency the filings report.
Source: SEC EDGAR (United States); every row links to where it was published. Event computed Sep 14, 2026.
Kevin Charles Gorman sold 245,088 NEUROCRINE BIOSCIENCES INC (NBIX) shares for $37,824,431 on May 19, 2026
Large trade for this person
Flagged because this trade was large compared with this person’s own earlier open-market trades in the same currency — not because it is large in absolute terms. A trade that is routine for one insider can be flagged for another.
Kevin Charles Gorman sold 245,088 NEUROCRINE BIOSCIENCES INC (NBIX) shares for $37,824,431 on May 19, 2026
Source: SEC EDGAR (United States); every row links to where it was published. Event computed Sep 14, 2026.
Kyle Gano sold 34,588 NEUROCRINE BIOSCIENCES INC (NBIX) shares for $4,589,828 on Jan 16, 2026
Large trade for this person
Flagged because this trade was large compared with this person’s own earlier open-market trades in the same currency — not because it is large in absolute terms. A trade that is routine for one insider can be flagged for another.
Kyle Gano sold 34,588 NEUROCRINE BIOSCIENCES INC (NBIX) shares for $4,589,828 on Jan 16, 2026
Source: SEC EDGAR (United States); every row links to where it was published. Event computed Sep 14, 2026.
Kevin Charles Gorman sold 106,322 NEUROCRINE BIOSCIENCES INC (NBIX) shares for $13,440,164 on Aug 7, 2025
Large trade for this person
Flagged because this trade was large compared with this person’s own earlier open-market trades in the same currency — not because it is large in absolute terms. A trade that is routine for one insider can be flagged for another.
Kevin Charles Gorman sold 106,322 NEUROCRINE BIOSCIENCES INC (NBIX) shares for $13,440,164 on Aug 7, 2025
Source: SEC EDGAR (United States); every row links to where it was published. Event computed Sep 14, 2026.
Recent insider transactions
Of the 356 rows we hold,
0 are open-market
purchases and
123 open-market
sales (S) — the only codes we count as buying or selling.i
The rest — awards, shares withheld to pay tax, option exercises, gifts and so on — follow from an employment contract or a transfer arranged off-market, not from a decision to buy or sell, so counting them would turn this into a pay table.
A price of 0.00 is a real reported figure on gifts (G) and share awards (A) — not a gap in our data.
Insider transactions disclosed to the SEC for NEUROCRINE BIOSCIENCES INC, newest first, each with the filing behind it.
From SEC Form 4 filings. Every row links to the filing it
came from. How we calculate this.
What a Form 4 isi
The report an officer, director or large shareholder must file after trading their own company’s stock.
Subsidiaries — 6 legal entities
Subsidiaries of NEUROCRINE BIOSCIENCES INC
6 legal entities named in the subsidiary exhibit filed with this company’s most recent 10-K. .
Filing on SEC.gov.
This is not the full list. SEC rules only require a company to name
its significant subsidiaries.
What that leaves outi
Smaller entities are left out of the exhibit entirely. A short list here means a short exhibit — it does not mean the company owns nothing else. Nothing on this page is inferred: every name below is copied from the filing.
Subsidiaries NEUROCRINE BIOSCIENCES INC names in its
most recent annual report, with the place each one is organised.
Subsidiary
Organised in
Neurocrine Continental, Inc.
Delaware, USA
Neurocrine Holdings Limited
England and Wales
Neurocrine International, Inc.
Delaware, USA
Neurocrine Ireland Limited
Ireland
Neurocrine Switzerland GmbH
Switzerland
Neurocrine Therapeutics Limited
Ireland
What counts as a subsidiaryi
A subsidiary is a separate legal entity this company controls; it is not the same thing as a brand, a division or an office. These entities do not file with the SEC in their own right, so there is no separate page to open for them.
Think a number here is wrong?
Open the linked filing and compare —
how to report it.
Sources and technical notes
Every figure on this page comes from filings to the U.S. SEC via EDGAR.
Nothing here is estimated, and nothing is taken from press coverage or company websites.
Share count: cover page of the latest filing (dei:EntityCommonStockSharesOutstanding), taken from
NEUROCRINE BIOSCIENCES INC’s own filings and multiplied by our closing price.
Full method.
What that share count meansi
the share count the company itself prints on the cover of its most recent filing, as of the date it signed that filing.
We do not take a market cap from a data vendor, and we do not estimate one: the figure
is a share count from NEUROCRINE BIOSCIENCES INC’s
own SEC filings multiplied by
the closing price we hold for the same stock.
